MX2017010795A - Proteínas biológicas condicionalmente activas. - Google Patents

Proteínas biológicas condicionalmente activas.

Info

Publication number
MX2017010795A
MX2017010795A MX2017010795A MX2017010795A MX2017010795A MX 2017010795 A MX2017010795 A MX 2017010795A MX 2017010795 A MX2017010795 A MX 2017010795A MX 2017010795 A MX2017010795 A MX 2017010795A MX 2017010795 A MX2017010795 A MX 2017010795A
Authority
MX
Mexico
Prior art keywords
proteins
conditionally active
methods
active biological
biological proteins
Prior art date
Application number
MX2017010795A
Other languages
English (en)
Inventor
Frey Gerhard
Wen Chang Hwai
M Short Jay
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of MX2017010795A publication Critical patent/MX2017010795A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para generar proteínas biológicas condicionalmente activas, en particular proteínas terapéuticas o de diagnóstico, que son más activas en una condición aberrante que en una condición fisiológica normal. Los métodos incluyen métodos de descubrimiento que utilizan bibliotecas de proteínas y ensayos que emplean concentraciones fisiológicas de componentes de fluidos corporales. Las proteínas biológicas condicionalmente activas se pueden evolucionar más, conjugarse a otras moléculas, enmascararse, reducir su actividad al unirlas a una fracción escindible. También se divulgan los criterios para seleccionar las proteínas de inicio para los métodos de descubrimiento, así como los formatos de las proteínas.
MX2017010795A 2015-02-24 2016-02-24 Proteínas biológicas condicionalmente activas. MX2017010795A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562120312P 2015-02-24 2015-02-24
US201562249907P 2015-11-02 2015-11-02
PCT/US2016/019242 WO2016138071A1 (en) 2015-02-24 2016-02-24 Conditionally active biological proteins

Publications (1)

Publication Number Publication Date
MX2017010795A true MX2017010795A (es) 2018-04-11

Family

ID=56789902

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010795A MX2017010795A (es) 2015-02-24 2016-02-24 Proteínas biológicas condicionalmente activas.
MX2020011052A MX2020011052A (es) 2015-02-24 2017-08-22 Proteinas biologicas condicionalmente activas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011052A MX2020011052A (es) 2015-02-24 2017-08-22 Proteinas biologicas condicionalmente activas.

Country Status (11)

Country Link
US (3) US10563194B2 (es)
EP (1) EP3262217A4 (es)
JP (3) JP7025214B2 (es)
KR (3) KR20210096326A (es)
CN (1) CN107580603A (es)
AU (1) AU2016222830B2 (es)
CA (2) CA3225013A1 (es)
MX (2) MX2017010795A (es)
RU (1) RU2733658C2 (es)
SG (2) SG11201705988UA (es)
WO (1) WO2016138071A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
AU2015259465A1 (en) * 2014-05-13 2016-11-17 Bioatla Llc Conditionally active biological proteins
CA2959141A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
TW202208441A (zh) * 2016-05-13 2022-03-01 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
KR20230145497A (ko) * 2016-08-31 2023-10-17 바이오아트라, 인코퍼레이티드 조건부 활성 폴리펩티드 및 이를 제조하는 방법
EP3541843A1 (en) 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP2020511951A (ja) * 2017-01-03 2020-04-23 バイオアトラ、エルエルシー 老化細胞の処置のためのタンパク質療法
JP2020512825A (ja) * 2017-04-12 2020-04-30 ファイザー・インク 条件的親和性を有する抗体およびその使用の方法
KR20210019464A (ko) 2018-06-05 2021-02-22 바이오아트라, 인코퍼레이티드 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도
MX2020013606A (es) * 2018-06-14 2021-05-27 Bioatla Inc Constructos de anticuerpos multiespecificos.
CN111505288B (zh) * 2020-05-15 2022-03-01 重庆医科大学 一种新的抑郁症生物标志物及其应用
CN114259460B (zh) * 2020-09-16 2024-03-15 苏州大学 基于免疫佐剂的水凝胶组合物及其应用
WO2023069892A1 (en) * 2021-10-19 2023-04-27 Short Jay M Conditionally active proteins for neurodegenerative diseases

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5632957A (en) 1993-11-01 1997-05-27 Nanogen Molecular biological diagnostic systems including electrodes
JPH05236997A (ja) 1992-02-28 1993-09-17 Hitachi Ltd ポリヌクレオチド捕捉用チップ
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5965452A (en) 1996-07-09 1999-10-12 Nanogen, Inc. Multiplexed active biologic array
US6468742B2 (en) 1993-11-01 2002-10-22 Nanogen, Inc. Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5959098A (en) 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
CN100390291C (zh) * 1995-11-28 2008-05-28 约翰斯·霍普金斯大学医学院 条件复制型病毒载体及其用法
US6022963A (en) 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
US6013440A (en) 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CN1107072C (zh) 1996-03-22 2003-04-30 人类基因组科学公司 编程性细胞死亡诱导分子ⅱ
AU3568897A (en) 1996-06-07 1998-01-05 Eos Biotechnology, Inc. Immobilised linear oligonucleotide arrays
US6826296B2 (en) 1997-07-25 2004-11-30 Affymetrix, Inc. Method and system for providing a probe array chip design database
AU8908198A (en) 1997-08-15 1999-03-08 Hyseq, Inc. Methods and compositions for detection or quantification of nucleic acid species
PT1012564E (pt) 1997-09-11 2003-08-29 Bioventures Inc Metodo de producao de arranjos de alta densidade
US6465178B2 (en) 1997-09-30 2002-10-15 Surmodics, Inc. Target molecule attachment to surfaces
WO1999023105A1 (en) 1997-11-03 1999-05-14 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
ATE340870T1 (de) 1998-04-03 2006-10-15 Compound Therapeutics Inc Adressierbare protein arrays
BRPI9909860B8 (pt) 1998-04-21 2021-05-25 Amgen Res Munich Gmbh polipeptídeo multifuncional de cadeia simples, polinucleotídeo, vetor, célula procariótica, de levedura ou unicelular, composição, usos de polipeptídeo e polinucleotídeo e métodos para preparo do referido polipeptídeo e para identificação de ativadores ou inibidores de ativação ou estimulação das células t
US6048695A (en) 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6277628B1 (en) 1998-10-02 2001-08-21 Incyte Genomics, Inc. Linear microarrays
US6277489B1 (en) 1998-12-04 2001-08-21 The Regents Of The University Of California Support for high performance affinity chromatography and other uses
US20090130718A1 (en) 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
US6221653B1 (en) 1999-04-27 2001-04-24 Agilent Technologies, Inc. Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids
US6653151B2 (en) 1999-07-30 2003-11-25 Large Scale Proteomics Corporation Dry deposition of materials for microarrays using matrix displacement
EP1106603A3 (en) 1999-12-06 2003-11-19 Fuji Photo Film Co., Ltd. DNA chip and reactive solid carrier
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
ATE448811T1 (de) 2001-04-27 2009-12-15 Vivoxid Oy Verfahren zur verbesserung der anhaftung von weichteilgewebe und implantate, die gebrauch von diesem verfahen machen
EP1511861A4 (en) 2002-06-12 2007-12-05 Genencor Int METHODS AND BINDING COMPOSITIONS DEPENDENT FROM THE MEDIUM OF A TARGET AGENT TO A TARGET
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
JP5010281B2 (ja) 2003-05-31 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
DK1716178T3 (da) 2004-02-16 2010-09-20 Micromet Ag Mindre immunogene bindingsmolekyler
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
EP1778728A2 (en) * 2004-08-19 2007-05-02 Genentech, Inc. Polypeptide variants with altered effector function
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
RS53905B1 (en) 2005-12-16 2015-08-31 Amgen Research (Munich) Gmbh METHODS AND TREATMENTS FOR TUMOR DISEASE
EP1981532A4 (en) 2005-12-21 2010-06-30 Medimmune Llc EPHA2 MOLECULES AND USES THEREOF
PT1976880T (pt) 2005-12-21 2016-09-28 Amgen Res (Munich) Gmbh Composições farmacêuticas com resistência a cea solúvel
EP2155788B1 (en) 2007-04-03 2012-06-27 Micromet AG Cross-species-specific bispecific binders
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
ES2558434T3 (es) 2008-11-07 2016-02-04 Amgen Research (Munich) Gmbh Tratamiento de leucemia linfoblástica aguda
BRPI0923748B1 (pt) 2008-12-31 2019-04-09 Metabolic Explorer Método para a preparação de dióis
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
ES2661310T3 (es) 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
WO2010127319A2 (en) 2009-04-30 2010-11-04 Genomatica, Inc. Organisms for the production of 1,3-butanediol
US8449773B2 (en) 2009-07-06 2013-05-28 Brigham Young University Method for pretreatment of cellulosic and lignocellulosic materials for conversion into bioenergy
CN102625848A (zh) 2009-07-17 2012-08-01 生物蛋白有限公司 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法
JP6121904B2 (ja) * 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
AU2012273177A1 (en) 2011-06-22 2013-05-02 Genomatica, Inc. Microorganisms for producing 1,3-butanediol and methods related thereto
CN113061993A (zh) 2011-09-30 2021-07-02 中外制药株式会社 离子浓度依赖性结合分子文库
CN104379602B (zh) * 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
US20140206596A1 (en) 2013-01-18 2014-07-24 University Of Southern California Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions

Also Published As

Publication number Publication date
US20200199578A1 (en) 2020-06-25
AU2021203506A1 (en) 2021-06-17
US20220127595A1 (en) 2022-04-28
RU2017127972A (ru) 2019-03-25
AU2016222830B2 (en) 2021-02-25
US11254932B2 (en) 2022-02-22
CA3225013A1 (en) 2016-09-01
MX2020011052A (es) 2020-11-06
EP3262217A4 (en) 2018-07-18
KR20210096326A (ko) 2021-08-04
KR20170117089A (ko) 2017-10-20
CN107580603A (zh) 2018-01-12
JP2023182651A (ja) 2023-12-26
SG11201705988UA (en) 2017-08-30
CA2977687C (en) 2024-02-13
EP3262217A1 (en) 2018-01-03
WO2016138071A1 (en) 2016-09-01
JP2022031720A (ja) 2022-02-22
KR102286801B1 (ko) 2021-08-09
SG10202108814VA (en) 2021-09-29
JP7025214B2 (ja) 2022-02-24
RU2733658C2 (ru) 2020-10-06
US10563194B2 (en) 2020-02-18
US20190024078A1 (en) 2019-01-24
RU2017127972A3 (es) 2019-08-09
AU2016222830A1 (en) 2017-08-10
CA2977687A1 (en) 2016-09-01
JP2018513206A (ja) 2018-05-24
KR20230109773A (ko) 2023-07-20

Similar Documents

Publication Publication Date Title
MX2020011052A (es) Proteinas biologicas condicionalmente activas.
MX2019007981A (es) Terapeutica de proteinas para el tratamiento de celulas senescentes.
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
MX2018004852A (es) Proteinas mirac.
WO2012040459A3 (en) Beta-catenin targeting peptides and uses thereof
MX340090B (es) Analogos de spliceostatina.
MY169745A (en) Purinone derivative
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
BR112015014752A2 (pt) compostos e métodos para modulação de cinase, e indicações para isto
UA95244C2 (ru) Соединения и способ модулирования активности киназ, и показания для их применения
MX349748B (es) Cánula escalonada.
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
MY200925A (en) Peptide Amide Compound and Preparation Method and Medical use Thereof
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
WO2014066915A3 (en) Methods and compositions to produce ss-rnai activity with enhanced potency
UY29046A1 (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
BR112014029346A2 (pt) sistema e método implementado por computador para a montagem de um plano de tratamento médico
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
GEP20156332B (en) Pyrazoles as crth2 antagonists
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
BR112013008420A2 (pt) composto, medicamento, e, uso do composito
EA201000864A1 (ru) Фенилоксетанильные производные
AU2009235634A8 (en) Substituted sulfonamide derivatives

Legal Events

Date Code Title Description
FG Grant or registration